Life Science Review Interview with our CEO, Dolores Baksh – May 2023

neDNA TAAV Enzymatic DNA Manufacturing Gene Therapy Dolores Baksh Life Science Review

The latest edition of Life Science Review covers our story!

There are many clinical trials targeted to treat rare diseases that are based on gene therapy techniques. A common element in most genetically based clinical studies is gene delivery systems, which include recombinant adeno associated viruses (rAAV).

These clinical trials require a critical starting material, such as plasmid DNA (pDNA).

While commonly employed, pDNA generation comprises long lead times due to a complicated bacteria-based manufacturing process, which often results in recombination and mutation events at the AAV inverted terminal repeats.

Discover how TAAV circumvents these hurdles by offering an alternative to plasmids — neDNA™, TAAV manufactured enzymatic DNA.

neDNA™ is produced using an enzymatic process that allows for rapid generation of DNA molecules, within a matter of days, leading to faster turnaround times and speed to clinic.

The generation of pDNA, by comparison, comprises long lead times due the E.coli-based manufacturing, a process with large footprint, that can result in low yields and heterogeneity of the final product due to the amplification of complex and unstable sequences, and even batch failure.

Read the full article here.

Happy Holidays 2023